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Th   ere is a growing recognition that the complex patho-
logic cascade that leads to Alzheimer’s disease (AD) 
begins decades before the development of clinical 
symptoms [1]. Th   is suggests that eﬀ  ective prevention will 
require predicting who will develop AD decades before 
the onset of symptoms. Th   erefore, there has been grow-
ing interest in developing accurate ways of identifying 
individuals who have an increased risk of developing 
symptomatic AD so that they can be targeted for 
preventive interventions such as risk factor reduction, 
behavioral modiﬁ  cation, or pharmacologic treatment.
Much of the current work on AD prediction, including 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
has focused on identifying biomarkers and neuroimaging 
tests that can accurately detect individuals with 
preclinical disease. Th   ese approaches implicitly recognize 
the multifaceted nature of the AD pathologic cascade 
(amyloid beta deposition, neuroﬁ  brillary tangles, neuronal 
dysfunction, and cerebral volume loss) [2] and rely on 
diﬀ   erent tests to capture diﬀ   erent aspects of that 
pathology. One recent analysis of ADNI data [3] found 
that a combination of magnetic resonance imaging 
(MRI), cerebrospinal ﬂ  uid, and neuropsychological and 
functional markers predicted conversion from mild 
cognitive impairment to AD with moderate accuracy 
(c statistic = 0.80). Th   e c statistic, also known as the area 
under the receiver operating characteristic curve, may 
range from 0 to 1, with 1 reﬂ  ecting perfect discrimination 
and 0.5 reﬂ  ecting no better than chance.
An alternative approach to the prediction of AD risk 
has been to identify combinations of traditional risk 
factors that can reliably diﬀ  erentiate individuals with a 
high risk of developing AD from those with a low risk. 
One study found that mid-life risk factors, including age, 
education, hypertension, hypercholesterolemia, and 
obesity, predicted late-life dementia risk with moderate 
accuracy (c statistic = 0.77) [4]. Another study found that 
a combination of late-life factors, including age, cognitive 
test scores, MRI measures, apolipoprotein E (APOE) 
geno  type, cardiovascular disease, and functional measures, 
also predicted dementia risk with moderate accuracy 
(c  statistic  = 0.82) [5]. An abbreviated version that 
included age and simpliﬁ  ed measures of cognitive func-
tion and cardiovascular disease had moderate accuracy 
as well (c statistic = 0.77) [6].
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treating high-risk older patients.
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© 2011 BioMed Central LtdAnother recent study extended this work by noting that 
a tremendous range of factors appear to predict AD, 
suggesting that AD is more likely in people with a broad 
decline in health. Song and colleagues [7] found that 19 
non-traditional risk factors such as a general health 
question (‘How good is your health?’) and sensory 
questions (‘How good is your eyesight or hearing?’) 
predicted which individuals were likely to develop AD, 
even after accounting for traditional risk factors such as 
age, sex, education, cognitive function, and cardio-
vascular disease. Implicit in this study is the assumption 
that, before leading to symptoms of cognitive impair-
ment, AD is associated with non-speciﬁ  c symptoms such 
as worse self-rated health. However, the prognostic 
accuracy of this model was only fair (c statistic = 0.66). In 
fact, in another study, demographics alone were found to 
be more predictive of dementia risk (c statistic = 0.72), 
and signiﬁ   cant increases in prognostic accuracy were 
associated with the addition of APOE genotype 
(c statistic = 0.75) and vascular risk factors (c statistic = 
0.79) [8].
Taken together, these studies suggest that there are a 
variety of approaches for identifying with fair to 
moderate levels of discrimination those individuals who 
are at high risk of developing AD. However, all of these 
models suﬀ  er from two important limitations in their 
approach to the prediction of AD risk.
First, none of these models explicitly accounts for the 
competing risk of death. AD is predominantly a disease 
of older adults who experience high rates of death from 
other causes. To eﬀ  ectively target preventive inter  ven-
tions  – in particular, pharmacologic interventions that 
may have adverse side eﬀ  ects – AD prediction models 
must identify individuals who are likely to suﬀ  er sympto-
matic AD before death. Many risk factors for AD are also 
risk factors for mortality (for example, older age, vascular 
risk factors, and functional limitations) [9]. Th  erefore, 
some patients who are at high risk for AD may be at even 
higher risk for death before symptomatic AD. To 
appropriately balance the potential beneﬁ  t of preventive 
intervention with the potential harm, AD prediction 
models must account for death and identify individuals 
whose risk of AD outweighs their risk of death.
Second, dementia risk models developed to date have 
been developed in cohort studies that focused on a 
limited range of potential predictors and had relatively 
short follow-up periods (<10 years) or relatively narrow 
risk windows (for example, mid-life only and late-life 
only). Th  us, these studies have not examined the full 
range of AD predictors (biomarkers, neuroimaging tech-
niques, and traditional and non-traditional risk factors) 
over the full 10- to 20-year preclinical risk period. Th  e 
ideal study would include repeated ascertainment of 
thousands of individuals over several decades, requiring a 
tremendous investment in resources. Furthermore, these 
prospectively collected data would not be available for 
decades, suggesting that alternative modeling techniques 
need to be employed. One possible solution is to use 
hidden Markov models [10], which potentially could be 
used to combine data from multiple sources to model 
disease state transitions across the full AD clinical-
pathologic spectrum.
In conclusion, prediction of AD risk is a relatively new 
ﬁ   eld of inquiry. Several alternative approaches with 
moderate levels of accuracy have been developed, but 
none is ready for widespread clinical use. As the ﬁ  eld 
moves forward, it will be critically important to develop 
techniques that simultaneously model the risk of 
mortality as well as the risk of AD over the full preclinical 
spectrum and to consider the potential harm as well as 
the beneﬁ   t of identifying and treating high-risk older 
patients.
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